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Article abstract—Objective: To analyze the relationship of specific motor impairment in idiopathic PD to incident
dementia. Background: The total Unified PD Rating Scale (UPDRS) motor score at baseline has been associated with an
increased risk of developing dementia in PD. Methods: A cohort of 214 nondemented community-dwelling patients with
PD was followed annually with neurologic and neuropsychological evaluations. The association of baseline motor impair-
ment with incident dementia was analyzed using Cox proportional hazards models. Facial expression, tremor, rigidity,
and bradykinesia were analyzed as part of subscore A (indicative of dopaminergic deficiency); speech and axial impair-
ment were analyzed as part of subscore B (indicative of predominantly nondopaminergic deficiency). The correlation
between the six motor domains and age was also analyzed. Results: Of 173 patients followed for at least 1 year, 50 became
demented according to the Diagnostic and Statistical Manual of Mental Disorders, revised 3rd edition (DSM III-R) criteria
(mean follow-up, 3.6 6 2.2 years). When both subscores A and B were entered into the Cox model, subscore B was
associated with incident dementia (relative risk 5 1.19; 95% CI, 1.09 to 1.30; p 5 0.0001), in addition to gender, age, and
education, whereas subscore A was not (relative risk 5 1.03; 95% CI, 0.99 to 1.07; p 5 0.19). Of the six motor domains,
speech and bradykinesia were associated with incident dementia (p , 0.05), and axial impairment approached signifi-
cance (p 5 0.06). Only axial impairment was correlated with age (correlation coefficient 5 0.32; p , 0.001). Conclusion:
The findings suggest that motor impairment mediated predominantly by nondopaminergic systems is associated with
incident dementia in PD. Axial impairment may be the result of a combined effect of the disease and the aging process.
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The relationship between specific motor signs and
cognitive abilities in idiopathic PD has been exten-
sively evaluated in cross-sectional studies including
both demented and nondemented patients.1-7 In lon-
gitudinal studies of patients with PD, age, severity of
extrapyramidal signs, depressive symptoms, and
specific neuropsychological impairment at baseline
have been independently associated with an in-
creased risk of developing dementia.8-11 However, the
association of specific motor impairment to incident
dementia in PD has rarely been explored.12,13
Some of the motor impairment in PD has been
attributed to nondopaminergic mechanisms, as
judged by specific signs being relatively refractory to
L-dopa therapy, especially in the middle and late
stages of the disease.14 In a cross-sectional study,15
the motor disability of patients with variable dura-
tion of PD was assessed when the L-dopa effect was
considered to be maximal and after withdrawal of
the medication. The effect of L-dopa on akinesia, ri-
gidity, and tremor remained stable over the different
lengths of disease duration, whereas percent im-
provement on L-dopa decreased for gait disorder, pos-
tural instability, and dysarthria. In other studies in
which patients with PD on L-dopa were followed for
10 or more years, abnormalities in gait, posture,
balance, and speech clearly worsened, whereas other
parkinsonian features improved, remained unchanged,
or rarely worsened.16,17 Thus, tremor, rigidity, and
bradykinesia may be viewed as representing more
purely dopaminergic manifestations of PD. In con-
trast, speech, posture, balance, and gait disorders
may be mediated by other neurotransmitter systems
in addition to dopamine.
The biologic basis of dementia in PD is controver-
sial. The correlation between motor and cognitive
impairment has been seen as evidence in favor of the
contribution of subcortical pathology to the develop-
ment of dementia in patients with PD.2,3,5 The analy-
sis of the relationship of specific motor impairment
to incident dementia may help clarify the relative
contribution of dopaminergic and nondopaminergic
neural systems to the development of dementia in
PD. We studied the association of Unified PD Rating
Scale (UPDRS) motor subscores at baseline and inci-
dent dementia in a community-dwelling cohort of non-
demented patients with PD followed longitudinally.
Methods. Subjects. A cohort of 214 nondemented pa-
tients with idiopathic PD from the Washington Heights
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community in northern Manhattan, New York was fol-
lowed annually with neurologic and neuropsychological
evaluations. The ascertainment procedure and inclusion
and exclusion criteria for the cohort have been described
previously.18 Thirty patients were not included in the anal-
ysis of the relationship of motor impairment at baseline to
incident dementia because they had only one visit. Four
patients were excluded because of signs or symptoms of
stroke, and data were incomplete for seven patients. Dura-
tion of PD was defined as the time period between the first
symptom of PD and the baseline evaluation. The neuropsy-
chological battery included tests of verbal and nonverbal
memory, orientation, visuospatial ability, language, and
verbal and nonverbal abstract reasoning; test scores were
evaluated using a fixed paradigm.19 The diagnosis of de-
mentia was based on the Diagnostic and Statistical Man-
ual of Mental Disorders, revised 3rd edition (DSM III-R).20
Data analysis. The analysis of the relationship of mo-
tor impairment to incident dementia in PD was performed
using Cox proportional hazards models. The UPDRS motor
examination (part III)21 was subdivided clinically into six
domains: speech, facial expression, tremor, rigidity, brady-
kinesia, and axial impairment (table 1). First, facial ex-
pression, tremor, rigidity, and bradykinesia were analyzed
as part of subscore A, and speech and axial impairment
were analyzed as part of subscore B. Second, in order to
further define the motor impairment associated with inci-
dent dementia in PD, the six domains of the UPDRS were
entered into the Cox model using a forward stepwise ap-
proach for the selection of predictor variables (entry crite-
rion: p , 0.05; removal criterion: p . 0.1). Duration of
follow-up until the diagnosis of dementia or until the last
visit for those patients that did not become demented was
used as the timing variable in the Cox model. The analyses
controlled for age, gender, education, duration of PD, use
of dopaminergic (including L-dopa and dopaminergic ago-
nists) and anticholinergic medications.
Because age may confound the relationship between
motor and cognitive impairment in PD, the correlation be-
tween the six domains of the UPDRS and age was also
studied using bivariate and partial correlation analysis.
Student’s t-tests and x2 tests were used for the comparison
of continuous and categorical variables at baseline.
Results. Of 173 patients, 50 became demented during a
mean follow-up period of 3.6 6 2.2 years. Baseline charac-
teristics of the cohort are summarized in table 2. Patients
that subsequently became demented were older, less edu-
cated, and had more severe motor signs at baseline than
those who did not become demented. No significant differ-
ences were seen in gender, ethnicity, duration of PD, lan-
guage in which the neuropsychological tests were
administered (English or Spanish), total Hamilton Depres-
sion Rating Scale22 score, use of dopaminergic and anticho-
linergic medications, or L-dopa dosage. The patients that
were excluded from the analysis due to missing data (n 5
7) were not significantly different from the other patients
in terms of gender, age, ethnicity, education, duration of
PD, or language in which the neuropsychological tests
were administered.
The total UPDRS motor score (range, 0 to 100) was
associated with incident dementia in the Cox model (rela-
tive risk [RR] 5 1.06; 95% CI, 1.04 to 1.09; p , 0.0001),
independent of demographic and medication variables.
This risk ratio means that a one-point difference in total
UPDRS motor scores between two subjects with similar
demographic profiles would be associated with a 6% in-
crease in risk of dementia over the 3.6 year follow-up pe-
riod. Both subscore A (RR 5 1.07; 95% CI, 1.03 to 1.10; p 5
0.0003) and subscore B (RR 5 1.23; 95% CI, 1.14 to 1.32;
p , 0.0001) were associated with incident dementia when
entered separately into the model. When both were en-
tered into the model, subscore B but not subscore A was
significantly associated with incident dementia. Male gen-
der, age at baseline, and education were also significantly
associated with incident dementia in this model (table 3).
The analysis was repeated using L-dopa dosage rather
than use of dopaminergic medications as a covariate. Nine-
teen additional cases were lost due to missing information
about L-dopa dosage; subscore B (RR 5 1.17; 95% CI, 1.06
to 1.29; p 5 0.002) was still associated with incident de-
mentia but subscore A (RR 5 1.04; 95% CI, 1.00 to 1.08;
p 5 0.07) was not. In a separate analysis including the six
domains of the UPDRS, speech and axial impairment (sub-
score B) as well as bradykinesia (subscore A) were retained
in the final model, although axial impairment approached
significance (table 4).
Among the six UPDRS motor domains, axial impair-
ment (Spearman’s rank correlation coefficient 5 0.29; p ,
0.001) (figure) and speech (Spearman’s rank correlation
coefficient 5 20.15; p 5 0.03) were correlated with age.
The motor domains, with the exception of tremor and ri-
gidity, were correlated with duration of PD ( p , 0.001).
When the analysis of the correlation between age and the
Table 1 Unified PD Rating Scale subscores
Total UPDRS* UPDRS domains and subscores




Tremor at rest (20 points)
Tremor (28
points)Action or postural tremor
(8 points)
Rigidity (20 points) Rigidity
(20 points)
Hand movements (8 points)
Bradykinesia
(28 points)
RAM of hands (8 points)
Leg agility (8 points)
Body bradykinesia and
hypokinesia (4 points)
Speech (4 points) Speech (4 points)
Subscore B
(20 points)





Postural stability (4 points)
Gait (4 points)
* Each single test of the UPDRS is rated from 0 (normal) to 4
(severe impairment); tremor at rest is evaluated in the four
limbs and face, rigidity is evaluated in the four limbs and neck,
and other tests are evaluated bilaterally either in the upper or
lower limbs.
RAM 5 rapid alternating movements; UPDRS 5 Unified PD
Rating Scale.
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motor domains was repeated controlling for duration of PD
and L-dopa dosage, the positive correlation between axial
impairment and age was still significant (correlation coef-
ficient 5 0.32; p , 0.001), but the negative correlation
between speech and age was not significant anymore (cor-
relation coefficient 5 20.13; p 5 0.09). Each of the four
tests of the UPDRS that were included in the axial impair-
ment domain (rising from a chair, posture, gait, and pos-
tural stability) were also significantly correlated with age.
Discussion. Our findings suggest that PD motor
impairment mediated predominantly by nondopa-
minergic systems is associated with incident demen-
tia. When the UPDRS total motor score was divided
in two subscores according to relative responsiveness
to dopaminergic therapy, motor impairment partially
responsive or nonresponsive to L-dopa (subscore B)
predicted the development of dementia in PD,
whereas in the same model, motor impairment re-
sponsive to L-dopa throughout the course of the dis-
ease (subscore A) did not. Among six domains of
extrapyramidal motor impairment in PD, speech and
bradykinesia predicted the development of incident
dementia, and axial impairment approached signifi-
cance in the Cox model.
Among the motor domains believed to respond to
L-dopa throughout the course of the disease, bradyki-
nesia was the only one to be significantly associated
with incident dementia. Indeed, bradykinesia has
been associated with cognitive impairment in PD in
many cross-sectional1-5 and longitudinal12,13 studies.
Other evidence, however, suggests a stronger rela-
tionship between non–L-dopa-responsive motor man-
ifestations and cognitive impairment in PD. In one
study,23 none of the neuropsychological test scores
was correlated with the L-dopa-responsive motor
score (the difference between the motor score after
withdrawal of L-dopa and the motor score on L-dopa








Age, y 74.3 (8.2) 69.4 (10.8)* 70.8 (10.3)
Education, y 9.5 (4.7) 11.8 (4.7)* 11.1 (4.8)
Gender, % male 56.0 43.1 46.8
Ethnicity, % white and non-Hispanic 56.0 53.7 54.3
Language, % English 51.0 64.8 60.8
Duration of PD, y 7.5 (5.9) 5.8 (7.3) 6.3 (7.0)
Total UPDRS score 31.4 (13.1) 22.0 (11.4)* 24.8 (12.6)
Total HDRS score† 7.0 (5.6) 5.6 (5.0) 6.0 (5.2)
Use of dopaminergic medications, %‡ 76.0 74.8 75.1
Use of anticholinergic medications, % 18.0 15.4 16.2
L-dopa dosage, mg/day§ 326.7 (325.3) 333.3 (335.4) 331.5 (331.6)
Values are expressed as mean (SD).
* p , 0.05.
† Total n 5 147.
‡ Includes L-dopa and dopaminergic agonists.
§ Total n 5 154.
HDRS 5 Hamilton Depression Rating Scale; UPDRS 5 Unified PD Rating scale.
Table 3 Risk ratios for incident dementia derived from a Cox
proportional hazards model including subscores A and B
Variable Risk ratio 95% CI p Value
Male gender 2.57 1.43–4.61 0.002
Age at baseline 1.09 1.05–1.13 ,0.0001
Education 0.93 0.88–0.99 0.02
Duration of PD 0.97 0.94–1.01 0.10
Use of DA 0.96 0.47–1.94 0.91
Use of anticholinergics 1.62 0.73–3.60 0.24
UPDRS subscore A 1.03 0.99–1.07 0.19
UPDRS subscore B 1.19 1.09–1.30 0.0001
DA 5 dopaminergic agent; UPDRS 5 Unified PD Rating Scale.
Table 4 Risk ratios for incident dementia derived from a Cox
proportional hazards model including UPDRS motor domains
Variable Risk ratio 95% CI p Value
Male gender 2.04 1.07–3.90 0.03
Age at baseline 1.11 1.06–1.15 ,0.0001
Education 0.95 0.89–1.01 0.09
Duration of PD 0.97 0.93–1.00 0.04
Use of DA 0.79 0.39–1.62 0.52
Use of anticholinergics 1.46 0.66–3.24 0.35
Speech 1.67 1.13–2.49 0.01
Bradykinesia 1.09 1.01–1.18 0.02
Axial impairment 1.11 0.99–1.24 0.06
DA 5 dopaminergic agent; UPDRS 5 Unified PD Rating Scale.
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treatment), but all were highly correlated with the
motor score on L-dopa treatment (motor impairment
not alleviated by L-dopa and presumed to be the re-
sult of nondopaminergic lesions). Moreover, cognitive
impairment was poorly correlated with akinesia and
rigidity, strongly correlated with gait disorder and
dysarthria, and not correlated with tremor at all. In
an analysis of the DATATOP cohort,24 a postural
instability and gait disorder subtype of PD was asso-
ciated with a more rapid disease progression and
greater subjective intellectual impairment as com-
pared with a tremor-dominant subtype of PD.
Among the six motor domains, only axial impair-
ment was significantly correlated with age in our
study. The relationship between gait and posture im-
pairment and age has been demonstrated in other
studies,4,25 and patients with young-onset PD are less
likely to complain of difficulty walking as an early
symptom compared with patients with late-onset
PD.26 Thus, age may act as a confounder and at least
partly explain the strong correlation of gait and pos-
tural disturbances with cognitive impairment in uni-
variate analyses. In one previous analysis,13 rigidity,
posture, gait, “bradykinesia of hands,” “upper ex-
tremity swing,” and “hoarseness and weakness of
speech” were significantly associated with dementia
in the univariate analysis. However, only bradykine-
sia and speech impairment were significant predic-
tors of dementia in a logistic regression model
controlling for age. In our analysis, the axial impair-
ment contribution to the Cox model controlling for
age and other covariates approached significance.
Extrapyramidal manifestations resembling parkin-
sonian features have long been recognized in normal
aging, including “an attitude of general flexion,” ri-
gidity, poverty of movement, bradykinesia, and gait
disorders.27 However, the unique correlation between
axial impairment and age in the setting of PD sug-
gests a combined effect of the disease and the aging
process.
The strengths of this study include the large co-
hort of community-dwelling patients with PD fol-
lowed for a relatively long period with neurologic and
neuropsychological evaluations, and its distinct
methodologic approach. Nevertheless, the implica-
tions of our findings for the contribution of dopami-
nergic and nondopaminergic mechanisms to the
development of dementia in PD rest upon the as-
sumption that nondopaminergic lesions play a pre-
dominant role in speech and axial impairment in the
middle and late stages of PD, and underlie the de-
clining L-dopa responsiveness over the course of the
disease.14,16 Although in a recent study bradykinesia
was the clinical sign of PD with the highest correla-
tion with the degree of nigrostriatal dopaminergic
deficit measured by fluorodopa PET,28 pathologic,
pharmacologic, and experimental animal data sug-
gest that dopamine is also related to rigidity and rest
tremor.29,30 Evidence from human parkinsonism due
to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
also indicates that dopamine deficiency may underlie
the three cardinal signs of PD.31 Other weaknesses of
this study include the lack of autopsy data allowing
for clinical-pathologic correlation, and the fact that
our cohort consisted of patients with a mean disease
duration at baseline of 6.3 years. Therefore, our results
may not be applicable to patients with early PD.
The role of nondopaminergic structures in the cog-
nitive manifestations of PD is supported by patho-
logic studies demonstrating greater involvement of
the basal forebrain32,33 and locus ceruleus34,35 in pa-
tients with PD and dementia compared with those
with PD without dementia. Loss of neurons in the
nucleus basalis of Meynert has been observed in PD
independently of Alzheimer-type cortical patholo-
gy.36,37 Nondopaminergic structures have also been
implicated in PD motor manifestations. Cell loss in
the pedunculopontine nucleus containing cholinergic
neurons (Ch5 cholinergic cell group38) has been
shown in PD and, to a greater extent, in progressive
supranuclear palsy.39-41 That the pedunculopontine
nucleus may play a role in the parkinsonian gait
disorder is supported by animal experimental stud-
ies showing its relationship to a mesencephalic loco-
motor region,42,43 and by its connections to the
thalamus, basal ganglia, subthalamic nucleus, and
substantia nigra, as well as to other sites in the
brainstem and spinal cord.44,45 The locus ceruleus
(noradrenergic), in turn, has been implicated in the
motor phenomenon of freezing46,47 and, through a fa-
cilitatory influence on nigrostriatal and mesolimbic
dopaminergic pathways, in locomotion behavior
based on animal studies.48,49
We believe that patients with PD with a greater
risk of developing dementia may exhibit a more
widespread neurotransmitter deficiency resulting
from subcortical pathology prior to the onset of de-
mentia. The brainstem nondopaminergic structures
(locus ceruleus and pedunculopontine nucleus) may
be involved in both motor impairment (subscore B)
and the development of dementia in PD, or degener-
ate in parallel with the cholinergic system of the
Figure. Scatterplot and fit line of axial impairment
versus age.
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basal forebrain. Moreover, axial motor impairment
in PD may be the result of a combined effect of the
disease and the aging process in brainstem nondo-
paminergic structures. To further clarify these issues,
clinical-pathologic correlation exploring cognitive func-
tion and specific motor manifestations of PD and dopa-
minergic as well as nondopaminergic anatomic
structures is needed.
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Cerebral blood flow and glucose
metabolism in mitochondrial disorders
M.J. Molna´r, MD, PhD; A. Valikovics, MD; S. Molna´r, MD; L. Tro´n, PhD; P. Dio´szeghy, MD, PhD;
F. Mechler, PhD; and B. Gulya´s, MD, PhD
Article abstract—Objective: To investigate cerebral metabolism by 2-[18F]fluorodeoxy-D-glucose (FDG) uptake using PET
and cerebrovascular reverse capacity by transcranial Doppler sonography (TCD) in different mitochondrial diseases
(mitochondrial myopathy; mitochondrial encephalopathy, lactacidosis, and stroke-like episodes [MELAS]; and chronic
external ophthalmoplegia). Background: Previous studies on individual patients with mitochondriopathies revealed abnor-
mal accumulations of mitochondria in endothelium, smooth muscle cells, and pericytes of blood vessels in different parts of
the nervous system (cerebrum, cerebellum, sural nerve) and skeletal muscle. On this basis, some investigators suggested a
pathogenic role of vascular involvement in the MELAS syndrome and other encephalopathies. Design/Methods: The
authors investigated neuronal metabolism and cerebrovascular involvement with PET in 5 cases and with TCD with
acetazolamide stimulation in 15 cases. The patients were divided into three groups: 1) interictal MELAS (n 5 4);
2) progressive external ophthalmoplegia (n 5 6); and 3) pure mitochondrial myopathy and neuropathy (n 5 5). The results
were compared with those from matched normal control subjects. The diagnoses were based on clinical phenotype as well
as histopathologic and molecular analysis. Results: Cerebral glucose uptake was impaired in all patients, both with and
without CNS symptoms, particularly in the occipital and temporal lobes. The vasoreactivity of the small arterioles to
acetazolamide did not differ significantly between the patients and healthy control subjects or between the different
groups of mitochondrial disorders. Conclusions: MELAS does not appear to be a functional disturbance of arterioles
leading to an ischemic vascular event. The clinical symptoms in MELAS are not the result of a mitochondrial angiopathy
but are the consequences of a mitochondrial cytopathy affecting neurons or glia. There is no correlation between the
decreased glucose metabolism and the duration of the disease.
NEUROLOGY 2000;55:544–548
Mitochondrial diseases are systemic disorders usu-
ally affecting multiple organs. Owing to the different
minimum energy requirements necessary for the
function of different organs, mitochondrial diseases
can result in tissue-specific disorders.1 The suscepti-
bility of the CNS to mitochondrial dysfunction
because of its high dependence on oxidative metabo-
lism has been well recognized.2 However, the func-
tional involvement of the CNS may be difficult to
detect. In certain mitochondrial encephalomyopa-
thies, characteristic changes may be found in the
CNS by CT.3 In some cases, diffuse hypodensity in
CT or increased water signal on MRI can be present
without clinical CNS symptoms; in turn, MRI or CT
signal changes may not yet be detectable when clini-
cal symptoms are already manifested. However, neu-
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